CD8A and neoplasm: Despite a TME favorable for aPD-1 therapy with increased CD8+ T cells and upregulation of PD-L1 on tumor cells after SOS1i+MEKi therapy, aPD-1+aCTLA-4+SOS1i+MEKi was still ineffective in decreasing tumor growth and increasing survival.